USANA (NYSE:USNA) misses Q3 2026 revenue estimates, stock drops 14.9%
USANA reported Q3 2026 revenue of $205.9M, missing estimates by 5.3% and down 3.6% YoY. Adjusted EPS was -$0.11, missing estimates by $0.22. The company lowered full-year revenue guidance to $900M and adjusted EPS to $0.55. Operating margin declined to -0.7%.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to trigger short‑term selling, but improved cash flow may offer a longer‑term upside if the company can reverse the trend.
Market read
The news is directly relevant to USANA shareholders and traders focusing on health‑supplement stocks.
What to watch
Cash flow turned positive and free cash flow improved, which could support a turnaround narrative.
Background
USANA is a nutrition and supplement company; the miss reflects weaker consumer demand and pricing pressure.
Ticker impact
USANA reported Q3 2026 revenue miss and cut full-year guidance, prompting a 14.9% stock drop.
downward pressure as investors price in weaker revenue and earnings outlook
Both revenue and EPS missed expectations and guidance was reduced, which historically triggers sell pressure.
Market effects
Potential drag on health‑supplement and nutrition sector as peers may face similar demand concerns.
Limited to US‑listed nutrition companies; no broader regional effect.
Minimal global impact beyond niche supplement market.
Counterpoint
If the miss is viewed as a temporary setback and the company can improve margins, the stock may be oversold.
Key entities
- CompanyUSANA Health Sciences
Subject of the earnings miss and guidance cut.
